Navigation Links
Johnson & Johnson Reports 2011 First-Quarter Results
Date:4/19/2011

thritis, and ankylosing spondylitis; and INVEGA® SUSTENNA™ (paliperidone palmitate) a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults.

Several other products also contributed to the operational sales growth including REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA® (darunavir), a treatment for HIV; CAELYX®  (pegylated liposomal doxorubicin hydrochloride), a treatment for certain types of cancer; LEVAQUIN®   (levofloxacin), a treatment for bacterial infections; and international sales of RISPERDAL® CONSTA® (risperidone), a long-acting injectable for the management of Bipolar I Disorder and schizophrenia.

During the quarter, the European Commission approved XEPLION® (paliperidone palmitate), a once monthly, long-acting injectable, antipsychotic, for the treatment of schizophrenia. In addition, the Company completed its tender offer for Crucell N.V., a global biopharmaceutical company focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide. Crucell now operates as the center for vaccines within the Johnson & Johnson pharmaceuticals group.

In April, the Company announced it had reached an agreement with Merck to amend the distribution rights to REMICADE® (infliximab) and SIMPONI® (golimumab), which treat chronic inflammatory diseases such as rheumatoid arthritis. The agreement concludes the arbitration proceeding initiated in 2009, requesting a ruling related to the distribution agreement following the announcement of the proposed merger between Merck and Schering-Plough.

Worldwide Medical Devices and Diagnostics sales of $6.4 billion for the first quarter represented an increase of 3.3% versus the prior year consisting of an operation
'/>"/>

SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
3. Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries
4. Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
5. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
6. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
7. U.S. Files Suit Against Johnson & Johnson For Paying Kickbacks to Nations Largest Nursing Home Pharmacy
8. EF Johnson Technologies Announces Third Quarter Results
9. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
10. Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference
11. Two Johnson & Johnson Subsidiaries to Pay Over $81 Million to Resolve Allegations of Off-Label Promotion of Topamax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... HYDERABAD, India , July 31, 2015 /PRNewswire/ ... Billing and CRM solutions for video, data and cloud ... (PoC) with a leading pharma giant for Internet ... managing different IoT applications offered on subscription model. ... Pharma giant is striving for business ...
(Date:7/30/2015)... COLUMBUS, Ohio, July 30, 2015 Mettler-Toledo International ... results for 2015.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... in the quarter. , Net earnings per diluted ... in the prior-year period. Adjusted EPS was $2.80 , ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 /PRNewswire/ ... that it will release its second quarter 2015 financial ... 6, 2015.   In conjunction with the release, the ... community at 5:00 p.m. Eastern Time on ... results of the quarter and other business developments. ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... 23, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) is ... and interactive website, www.solosendoscopy.com on Friday July ... catalog" for existing and new customers and includes comprehensive ... updated look showcases streamlined navigation to allow for easy-to-use ...
... GAITHERSBURG, Md., June 23, 2011 Sirnaomics, Inc. ... has signed a partnership agreement with Guangdong Zhongsheng ... on the Shenzhen Stock Exchange (SZSE: 002317). The ... RNA (siRNA) therapeutics to treat diabetic retinopathy and ...
Cached Medicine Technology:Solos Endoscopy, Inc. To Launch New Corporate Website 2Sirnaomics Seals a Second Partnership Deal with a Chinese Pharmaceutical Company for Developing siRNA Therapeutics 2Sirnaomics Seals a Second Partnership Deal with a Chinese Pharmaceutical Company for Developing siRNA Therapeutics 3
(Date:8/1/2015)... (PRWEB) , ... August 02, 2015 , ... Back packs ... in a school, however, back packs can wreck havoc on a kid's spine. With ... their supplies to and from school. Make sure you are aware of how to ...
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... Tina Wilcoxson, ... Champions.” , Wilcoxson was given that honor by the National Retail Federation, the largest ... industry. Wilcoxson was one of three Maine business owners to be named as such. ...
(Date:8/1/2015)... ... ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair Care, has announced ... donation to kick off the campaign for healing and Well-Being. , BeverlyD has helped ... line of raw, organic hair care products, as well as her book, Hair Now!— ...
(Date:7/31/2015)... ... , ... When the weather turned hot and warm-season turfgrasses, such as zoysia ... Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names are ... type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure Time ...
(Date:7/31/2015)... ... 2015 , ... Recently touted by Becker’s Healthcare as one ... , Jvion continues to disrupt the predictive analytic and big data market using ... population level illness to drive prevention and better health outcomes. Most recently, Jvion ...
Breaking Medicine News(10 mins):Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2
... found in the River Cam in Cambridge, famous as ... lazy summer days, could become the next generation of ... 2007) at the Society for General Microbiologys 161st Meeting ... 3-6 September 2007. , With antibiotics now over-prescribed for ...
... of schizophrenia, INDIANAPOLIS, Sept. 2 An investigational,phase ... that for the first time in humans a drug ... has antipsychotic activity. The study,was sponsored by Eli Lilly ... study - a randomized, double-blind, placebo-controlled clinical,trial - patients ...
... known as a troublemaker for triggering the itch and inflammation ... the flare-ups, researchers from Stanford University School of Medicine have ... the online version of Nature Immunology, reveal that, in mice, ... exposure or from poison oak. , "These reactions are much ...
... Chinas efforts to control population growth in the present ... the future. , This prediction comes from a Saint ... year in China studying its geriatric policies and practices. ... internal medicine in the division of geriatric medicine at ...
... A nanoparticle drug delivery system designed for brain tumour ... novel cell culture model devised by scientists at The ... Schools of Pharmacy, Biomedical Sciences and Human Development, will ... Biology and Medicine. , Therapy for brain cancers is ...
... an important drug used in the treatment of malignant melanoma ... activates immune-system cells to fight the disease. , The ... microscopic tumor cells that may remain in the body following ... for this purpose. , Researchers say that these findings ...
Cached Medicine News:Health News:New viruses to treat bacterial diseases -- 'My enemies' enemy is my friend' 2Health News:Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 2Health News:Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 3Health News:Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 4Health News:Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 5Health News:Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 6Health News:Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find 2Health News:Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find 3Health News:China's 1-child policy could backfire on its elderly 2Health News:China's 1-child policy could backfire on its elderly 3Health News:Novel 3-D cell culture model shows selective tumour uptake of nanoparticles 2Health News:Melanoma drug revs immune cells but cancer cells ignore it 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: